What is NMRA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.07B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for NMRA?

P/E (TTM) is n/a and 52-week range is $0.32 to $3.65 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s NMRA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for NMRA?

The company profile lists net income (TTM) near -$232M, EPS (TTM) near -$1.23 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Neumora Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Watertown, Massachusetts, US, 187.9M shares outstanding, ISIN US6409791000 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Neumora Therapeutics Inc

$NMRA

Health Care · Pharmaceuticals

Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. The company is headquartered in Watertown, Massachusetts and currently employs 63 full-time employees. The company went IPO on 2023-09-15. The firm's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The firm's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).

Employees

Website

neumoratx.com/

IPO

2023-09-15

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US6409791000

Headquarters

Watertown, Massachusetts, US

Shares outstanding

187.9M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

58.97%

Browse other companiesFree AI scores and summaries for more stocks